Skip to content

Author

Ahmed S. A. Osman

We have 2 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).

Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.